Drugmaker Valeant raises bid for Dendreon cancer vaccine

February 5, 2015 4:06 PM

8 0

(Reuters) - Valeant Pharmaceuticals International Inc said on Thursday it has raised its bid for worldwide rights to a prostate cancer vaccine owned by bankrupt drugmaker Dendreon Corp.

Laval, Quebec-based Valeant said that in response to competing bids, it has hiked its bid to $400 million in cash from $296 million for the drug, called Provenge, and certain other assets.

Read more

To category page